Plural Carboxamide Groups Or Plural C=o Groups Bonded Directly To The Same Nitrogen Patents (Class 514/616)
-
Patent number: 8618172Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations of these.Type: GrantFiled: June 21, 2007Date of Patent: December 31, 2013Assignee: Novartis AGInventor: Matthias Willmann
-
Patent number: 8613949Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Amlodipine, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50% or more after 20 minutes, and 70% or more after 30 minutes at pH 2, said pharmaceutical oral fixed dose combination being bioequivalent, or close to reaching bioequivalence, to a free dose combination of Aliskiren and Amlodipine.Type: GrantFiled: September 22, 2009Date of Patent: December 24, 2013Assignee: Novartis AGInventors: Stephen Valazza, Robert F Wagner, Sudha Vippagunta
-
Patent number: 8614238Abstract: The invention relates to cyclopentanecarboxamide derivatives of formula 1, to their use as Fatty Acid Synthase inhibitors, to methods for their therapeutic use and to pharmaceutical compositions containing them, wherein R1, R2, R3, LO, W, AR1, n are as defined in claim 1.Type: GrantFiled: October 15, 2010Date of Patent: December 24, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Joerg Kley, Bradford S. Hamilton, Juergen Mack, Norbert Redemann, Corinna Schoelch
-
Publication number: 20130338092Abstract: This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.Type: ApplicationFiled: August 16, 2013Publication date: December 19, 2013Inventors: Kimberly Hartwell, Malcolm A.S. Moore, David T. Scadden, Stuart L. Schreiber, Todd R. Golub, Benito Munoz, Benjamin L. Ebert, Andrew M. Stern, Peter G. Miller, D. Gary Gilliland, Anne Van Dyk Carpenter, David J. Logan, Joseph Negri, Nicola Tolliday, Alykhan Shamji, Siddhartha Mukherjee, Alison Stewart
-
Patent number: 8609721Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.Type: GrantFiled: February 11, 2008Date of Patent: December 17, 2013Assignee: Georgetown UniversityInventors: Alan P. Kozikowski, Jarda T. Wroblewski, Fajun Nan
-
Publication number: 20130331411Abstract: The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.Type: ApplicationFiled: September 23, 2011Publication date: December 12, 2013Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, THE BROAD INSTITUTE, INC.Inventors: Chris Dockendorff, Robert Flaumenhaft, Lawrence MacPherson
-
Publication number: 20130331313Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.Type: ApplicationFiled: June 7, 2013Publication date: December 12, 2013Inventors: Ronald J. Berenson, Douglas V. Faller
-
Patent number: 8598234Abstract: A biocidal composition comprising 2,2-dibromomalonamide and sodium ortho-phenylphenol, and its use for the control of microorganisms in aqueous and water-containing systems.Type: GrantFiled: September 27, 2010Date of Patent: December 3, 2013Assignee: Dow Global Technologies LLCInventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20130317030Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 7, 2013Publication date: November 28, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
-
Publication number: 20130317109Abstract: There is provided a process for the preparation of Lacosamide (which is a useful medicament) of formula I, which comprises an enantioselective enzymatic acylation.Type: ApplicationFiled: November 25, 2011Publication date: November 28, 2013Applicant: CAMBREX KARLSKOGA ABInventors: Cecilia Kvarnström Branneby, Margus Eek
-
Publication number: 20130317084Abstract: The present invention relates to a method for treating a subject having or at risk of a diabetes-related disorder. In a preferred embodiment, the method involves increasing the level or activity of Hypoxia Induced Factor 1 (HIF-1?) in pancreatic-?-cells or insulin-sensitive tissues in the subject by administering to the subject an inhibitor of a protein that decreases the level or activity of HIF-1?. The present invention also relates to a method of transplanting pancreatic islet cells in a subject.Type: ApplicationFiled: August 2, 2013Publication date: November 28, 2013Applicant: Garvan Institute of Medical Research C/-St. Vincent's HospitalInventor: Jenny Gunton
-
Patent number: 8592485Abstract: The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b.Type: GrantFiled: June 16, 2011Date of Patent: November 26, 2013Assignee: HealthPartners Research FoundationInventors: Leah Ranae Bresin Hanson, William H. Frey, II
-
Publication number: 20130310386Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.Type: ApplicationFiled: November 10, 2011Publication date: November 21, 2013Applicant: Fibrotech Therapeutics Pty LtdInventors: Darren James Kelly, David Stapleton
-
Publication number: 20130310459Abstract: An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclic. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R1 and R2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G1)-Q1 or —C(=G1)-G2Q2, and G1 to G3 each represent oxygen atoms or the like. Q1 and Q2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y1 and Y5 each represent a halogen atom or the like, Y2 and Y4 each represent a hydrogen atom or the like, and Y3 represents a C2-C5 haloalkyl group.Type: ApplicationFiled: July 24, 2013Publication date: November 21, 2013Applicant: Mitsui Chemicals Agro, Inc.Inventors: Yumi Kobayashi, Hidenori Daido, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Yusuke Takahashi, Yoji Aoki, Atsuko Kawahara, Yasuaki Fukazawa, Mai Hirose
-
Publication number: 20130287688Abstract: Methods and compositions for improving the delivery and/or efficacy of a therapy (e.g., a cancer therapy) are disclosed. In one embodiment, methods and compositions for treating or preventing a cancer (e.g., a solid tumor such as a desmoplastic tumor) by administering to a subject an anti-hypertensive agent, as a single agent or in combination with a microenvironment modulator and/or a therapy, e.g., a cancer therapy (for example, a therapeutic agent or therapy, including immunotherapy (e.g., antibodies, vaccine, cell-based), nanotherapeutics, radiation therapy, photodynamic therapy, low molecular weight chemotherapeutics, molecularly targeted therapeutics and/or oxygen radical) are disclosed.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Applicants: XTUIT PHARMACEUTICALS, INC., THE GENERAL HOSPITAL CORPORATIONInventors: The General Hospital Corporation, Xtuit Pharmaceuticals, Inc.
-
Publication number: 20130289112Abstract: Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.Type: ApplicationFiled: March 21, 2011Publication date: October 31, 2013Applicant: TIANJIN CHASESUN PHARMACEUTICAL CO., LTDInventors: Jiang Zheng, Xinchuan Zheng, Xin Liu, Hong Zhou, Ning Wang, Hongwei Cao, Yan Li, Yongling Lu, Kecen Zhao, Jingcheng Yang, Yang Yang, Yuanfeng Zhu, Guo Wei, Min Huang
-
Patent number: 8569381Abstract: The present invention includes a combination comprising: a) mecamylamine; and b) an ACE inhibitor, an AT2 receptor inhibitor, a renin inhibitor, or a combination thereof.Type: GrantFiled: May 22, 2009Date of Patent: October 29, 2013Assignee: Targacept, Inc.Inventors: Steven M. Toler, David A. Hosford
-
Patent number: 8563736Abstract: A compound represented by Formula (1): The compound can be used as insecticides.Type: GrantFiled: March 22, 2012Date of Patent: October 22, 2013Assignee: Mitsui Chemicals, Inc.Inventors: Kei Yoshida, Takeo Wakita, Hiroyuki Katsuta, Akiyoshi Kai, Yutaka Chiba, Kiyoshi Takahashi, Hiroko Kato, Nobuyuki Kawahara, Michikazu Nomura, Hidenori Daido, Junji Maki, Shinichi Banba
-
Patent number: 8563714Abstract: The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases.Type: GrantFiled: May 17, 2010Date of Patent: October 22, 2013Assignee: Actelion Pharmaceuticals Ltd.Inventors: Daniel Bur, Olivier Corminboeuf, Sylvaine Cren, Corinna Grisostomi, Xavier Leroy, Sylvia Richard-Bildstein
-
Publication number: 20130274246Abstract: The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic and/or serotonin neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient.Type: ApplicationFiled: June 6, 2011Publication date: October 17, 2013Inventor: Anthony H. Cincotta
-
Publication number: 20130261132Abstract: Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds.Type: ApplicationFiled: November 21, 2011Publication date: October 3, 2013Applicant: LEO PHARMA A/SInventors: Per Vedso, Lars Kristian Albert BlÆher
-
Publication number: 20130261052Abstract: Proteases such as memapsin-1 are import enzymes, playing roles in a variety of diseases including diabetes. The inventors have developed inhibitors of memapsin 1 and methods of use therefore in the treatment of disease.Type: ApplicationFiled: March 11, 2013Publication date: October 3, 2013Applicant: Oklahoma Medical Research FoundationInventors: Jordan Tang, Xiangping Huang, Deborah Downs
-
Publication number: 20130251803Abstract: A modified release formulation of lacosamide suitable for once-daily administration.Type: ApplicationFiled: December 1, 2011Publication date: September 26, 2013Applicant: UCB PHARMA GMBHInventors: Willi Cawello, Martin Alexander Schubert
-
Publication number: 20130252964Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.Type: ApplicationFiled: January 18, 2013Publication date: September 26, 2013Applicant: PolyMedix, Inc.Inventors: Richard W. Scott, Katie Freeman, Haizhong Tang, Gill Diamond
-
Publication number: 20130251813Abstract: A modified release formulation of lacosamide.Type: ApplicationFiled: December 1, 2011Publication date: September 26, 2013Applicant: UCB PHARMA GMBHInventors: Willi Cawello, Martin Alexander Schubert
-
Patent number: 8541473Abstract: A 3-aminooxalylaminobenzamide compound is used as an insecticide or miticide. The 3-aminooxalylaminobenzamide compound is represented by formula [1]: in which, for instance, R1 and R2 each represent a C1 to C3 alkoxy group or a C1 to C3 haloalkoxy group; R3 and R4 each represent a C1 to C8 alkyl group or a C1 to C8 haloalkyl group; R5 represents a C1 to C5 haloalkyl group; R6 and R7 each represent a hydrogen atom or a C1 to C5 alkyl group; Y represents a hydrogen atom or a halogen atom; Z represents a hydrogen atom; n is an integer ranging from 0 to 4; and m is an integer ranging from 0 to 2.Type: GrantFiled: February 5, 2010Date of Patent: September 24, 2013Assignee: Agro-Kanesho Co., Ltd.Inventors: Shuichi Usui, Toshiki Fukuchi, Sachiko Kinoshita
-
Patent number: 8541620Abstract: The present invention relates to a method for selectively crystallizing Z isomer of iopromide of formula (I) comprising a) dissolving a crude iopromide comprising a mixture of E and Z isomers or a concentrate thereof in an alcohol, and b) heating the resulting alcohol solution to obtain crystalline of Z isomer of iopromide; and a method for preparing a composition comprising the crystalline Z isomer of iopromide.Type: GrantFiled: October 21, 2009Date of Patent: September 24, 2013Assignee: Daewoong Pharmaceutical Co., Ltd.Inventors: Soo-Jin Choi, Byung-Goo Lee, Han-Kuk Lee, Young-Mook Lim, Wol-Young Kim, Joon-Hwan Lee
-
Publication number: 20130244952Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 11, 2012Publication date: September 19, 2013Applicant: Abraxis BioScience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Publication number: 20130245064Abstract: The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein R1 is phenyl substituted by phenyl, phenoxy, phenylamino or heteroaryl, all optionally further substituted; bicyclic aryl, monocyclic heteroaryl substituted by optionally substituted phenyl, or bicyclic heteroaryl, R2 is hydrogen or methyl, and R3 and R4 have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers.Type: ApplicationFiled: October 31, 2011Publication date: September 19, 2013Inventors: Shaheen Ahmed, Stefan Hettwer, Jan Willem Vrijbloed, Carlo Farina, Piero Paravidino
-
Publication number: 20130237604Abstract: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM).Type: ApplicationFiled: April 18, 2013Publication date: September 12, 2013Applicant: Lasser Family Partnership, L.P.Inventors: Elliott C. Lasser, Kenneth H. Lasser
-
Patent number: 8530521Abstract: A compound having the structure wherein Y is selected from the group consisting of —C(O)OR2, —C(O)NHR8, —C(CH2)1-2OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.Type: GrantFiled: July 27, 2009Date of Patent: September 10, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Robert K. Baker, Kathleen M. Rupprecht, Michael Man-Chu Lo, Brent Whitehead
-
Publication number: 20130231392Abstract: An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclic. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R1 and R2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G1)-Q1 or —C(=G1)-G2Q2, and G1 to G3 each represent oxygen atoms or the like. Q1 and Q2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y1 and Y5 each represent a halogen atom or the like, Y2 and Y4 each represent a hydrogen atom or the like, and Y3 represents a C2-C5 haloalkyl group.Type: ApplicationFiled: March 18, 2013Publication date: September 5, 2013Applicant: MITSUI CHEMICALS ARGO, INC.Inventors: Yumi Kobayashi, Hidenori Daido, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Yusuke Takahashi, Yoji Aoki, Atsuko Kawahara, Yasuaki Fukazawa, Mai Hirose
-
Publication number: 20130231385Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.Type: ApplicationFiled: May 27, 2011Publication date: September 5, 2013Applicant: The Board of Regents of the University of Texas SystemsInventors: Jung-Mo Ahn, Ganesh Raj
-
Publication number: 20130231323Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.Type: ApplicationFiled: September 6, 2011Publication date: September 5, 2013Applicant: DUKE UNIVERSITYInventors: Pei Zhou, Eric J. Toone
-
Publication number: 20130225686Abstract: The invention relates to solid forms of the anti-epileptic agent lacosamide (I). The invention also relates to mixtures of solid forms of lacosamide. The invention further relates to mixtures of lacosamide enantiomers crystallized in a conglomerate Form and the use thereof in providing enantiomerically enriched lacosamide, preferably lacosamide enriched with the (R)-enantiomer of lacosamide.Type: ApplicationFiled: April 12, 2013Publication date: August 29, 2013Applicant: Medichem, S.A.Inventor: Medichem, S.A.
-
Patent number: 8518979Abstract: Novel Alpha-halo- and Alpha-alkyl-cyclopropylcarboxy compounds, and uses of these and related compounds in the treatment of a variety of neurological diseases and disorders, and particularly epilepsy, are provided.Type: GrantFiled: February 19, 2008Date of Patent: August 27, 2013Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Meir Bialer, Boris Yagen, Neta Pessah
-
Publication number: 20130217660Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.Type: ApplicationFiled: May 12, 2011Publication date: August 22, 2013Inventors: Dong-Ming Shen, John S. Debenham, Thomas H. Graham, Matthew J. Clements, Yong Zhang
-
Patent number: 8513235Abstract: The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.Type: GrantFiled: April 10, 2009Date of Patent: August 20, 2013Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Akira Nakao, Hiroko Suzuki, Ryo Tatsumi, Maki Seki, Minoru Tanaka, Tomofumi Setsuta, Hiroshi Iwasaki
-
Publication number: 20130210918Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.Type: ApplicationFiled: April 15, 2013Publication date: August 15, 2013Applicant: The Scripps Research InstituteInventors: Joel M. Gottesfeld, Kai Jenssen, David M. Herman, Ryan Burnett, C. James Chou
-
Publication number: 20130210887Abstract: The present invention relates to novel compounds of general formula (I) and (II) for their use in gene therapy as non-viral vehicles and their use for the preparation of a medicament. It also discloses the process of synthesis of said compounds of general formula (I) and (II).Type: ApplicationFiled: March 4, 2011Publication date: August 15, 2013Applicant: UNIVERSIDAD DE CASTILLA LA MANCHAInventors: Valentin Cena Callejo, Maria Del Prado Sánchez Verdu, Sonia Merino Guijarro, Joaquin Calixto García Martínez, Julián Rodríguez López, Ester Vázquez Fernández-Pacheco, María Antonia Herrero Chamorro, Ana Campo Rodrigo, Iván Rivilla De La Cruz, Francisco Carlos Pérez Martínez, Francisco Javier Guerra Navarro
-
Publication number: 20130210744Abstract: Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative thereof; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anticancer-associated fibroblast composition; and a method for treatment of cancer.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: NITTO DENKO CORPORATIONInventor: Nitto Denko Corporation
-
Patent number: 8501813Abstract: It is intended to provide a novel compound that has an excellent ?-secretase inhibitory effect and specifically inhibits A? production. The present invention provides a compound of the following formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a linear or branched alkyl group having 1 to 4 carbon atoms or a phenyl group; R2 represents a linear or branched alkyl group having 1 to 4 carbon atoms which may be substituted by one or more phenyl or halogenophenyl groups; R3 represents a linear or branched alkyl group having 1 to 4 carbon atoms which may be substituted by one or more hydroxyl groups; R4 represents a linear or branched alkyl group having 1 to 4 carbon atoms; and the symbol “*” represents a chiral center.Type: GrantFiled: July 1, 2008Date of Patent: August 6, 2013Assignee: Kabushiki Kaisha Yakult HonshaInventors: Atsuhiro Abe, Hideaki Shimizu, Seigo Sawada, Hiroshi Kodaira
-
Publication number: 20130196977Abstract: The present invention provides methods for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with (i) an ACE inhibitor or a pharmaceutically acceptable salt thereof; or (II) an angiotensin II receptor blocker or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 10, 2012Publication date: August 1, 2013Inventors: David Louis FELDMAN, Friedrich Cameron LUFT, Dominik Nicolas Mueller, Randy Lee Webb
-
Publication number: 20130195988Abstract: A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 ?m. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: Shanghai Cancer InstituteInventor: Shanghai Cancer Institute
-
Patent number: 8497228Abstract: The present invention relates to novel active substance combinations which contain firstly at least one known compound of the formula (I) in which R1 and A have the meanings given in the description, and secondly at least one further known active substance from the class of the phthalic diamides, and which are highly suitable for controlling animal pests such as insects and undesired acarids.Type: GrantFiled: August 26, 2008Date of Patent: July 30, 2013Assignee: Bayer Cropscience AGInventors: Heike Hungenberg, Peter Jeschke, Robert Velten, Rüduger Fischer, Wolfgang Thielert
-
Patent number: 8497397Abstract: A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].Type: GrantFiled: February 24, 2012Date of Patent: July 30, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Kazumasa Aoki, Koji Suda, Toshio Kaneko, Tomio Kimura
-
Publication number: 20130190340Abstract: Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein.Type: ApplicationFiled: June 30, 2011Publication date: July 25, 2013Applicant: Brandeis UniversityInventors: Lizbeth K. Hedstrom, Marcus Long, Deviprasad R. Gollapalli
-
Publication number: 20130190364Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more diamide compound(s) selected from Group (A) shows an excellent controlling activity on a pest.Type: ApplicationFiled: October 13, 2011Publication date: July 25, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka
-
Publication number: 20130189333Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.Type: ApplicationFiled: January 18, 2013Publication date: July 25, 2013Applicant: ALTRIA CLIENT SERVICES INC.Inventor: Altria Client Services Inc.
-
Publication number: 20130190327Abstract: The invention relates to bis-fatty acid conjugates; compositions comprising an effective amount of a bis-fatty acid conjugate; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a bis-fatty acid conjugate.Type: ApplicationFiled: February 25, 2011Publication date: July 25, 2013Applicant: CATABASIS PHARMACEUTICALS INCInventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu